The stock of Nektar Therapeutics (NASDAQ: NKTR) has decreased by -1.69 when compared to last closing price of 0.85. Despite this, the company has experienced a -21.63% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-24 that — TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study — SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar’s rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D). Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways.
Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?
The 36-month beta value for NKTR is also noteworthy at 0.66. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for NKTR is 177.74M, and at present, short sellers hold a 3.24% of that float. The average trading volume of NKTR on February 25, 2025 was 2.20M shares.
NKTR’s Market Performance
NKTR stock saw a decrease of -21.63% in the past week, with a monthly decline of -6.12% and a quarterly a decrease of -16.93%. The volatility ratio for the week is 8.77%, and the volatility levels for the last 30 days are 9.67% for Nektar Therapeutics (NKTR). The simple moving average for the past 20 days is -0.35% for NKTR’s stock, with a -30.77% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with B. Riley Securities repeating the rating for NKTR by listing it as a “Buy.” The predicted price for NKTR in the upcoming period, according to B. Riley Securities is $4 based on the research report published on January 08, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $6.50. The rating they have provided for NKTR stocks is “Buy” according to the report published on December 10th, 2024.
Piper Sandler gave a rating of “Overweight” to NKTR, setting the target price at $7 in the report published on November 04th of the previous year.
NKTR Trading at -9.15% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.91% of loss for the given period.
Volatility was left at 9.67%, however, over the last 30 days, the volatility rate increased by 8.77%, as shares sank -6.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.08% lower at present.
During the last 5 trading sessions, NKTR fell by -23.09%, which changed the moving average for the period of 200-days by -45.65% in comparison to the 20-day moving average, which settled at $0.8329. In addition, Nektar Therapeutics saw -10.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from Zalevsky Jonathan, who sale 10,300 shares at the price of $1.01 back on Feb 19 ’25. After this action, Zalevsky Jonathan now owns 316,604 shares of Nektar Therapeutics, valued at $10,403 using the latest closing price.
Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 11,040 shares at $1.01 during a trade that took place back on Feb 19 ’25, which means that Wilson Mark Andrew is holding 324,292 shares at $11,150 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.46 for the present operating margin
- 0.68 for the gross margin
The net margin for Nektar Therapeutics stands at -1.81. The total capital return value is set at -0.57. Equity return is now at value -161.63, with -44.87 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -1.63. The debt to equity ratio resting at 2.21. The interest coverage ratio of the stock is -5.48.
Currently, EBITDA for the company is -243.11 million with net debt to EBITDA at -0.57. When we switch over and look at the enterprise to sales, we see a ratio of 2.52. The receivables turnover for the company is 43.87for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.24.
Conclusion
In summary, Nektar Therapeutics (NKTR) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
